A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: TAK-079
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: Pomalidomide

Sponsor

Takeda